预约演示
更新于：2025-07-21
Epinastine Hydrochloride
盐酸依匹斯汀
更新于：2025-07-21
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16ClN3 |
InChIKeyVKXSGUIOOQPGAF-UHFFFAOYSA-N |
CAS号108929-04-0 |
关联
50
项与 盐酸依匹斯汀 相关的临床试验CTR20243732
盐酸依匹斯汀片在健康受试者中的单中心、随机、开放、单次给药、两制剂、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
CTR20234212
0.1%STN1011403滴眼液治疗过敏性结膜炎的多中心随机评价者盲态阳性对照试验
CTR20231572
0.05%盐酸依匹斯汀滴眼液治疗中国过敏性结膜炎患者的有效性和安全性的随机、双盲、阳性药平行对照、多中心临床研究
100 项与 盐酸依匹斯汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸依匹斯汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸依匹斯汀 相关的专利（医药）
登录后查看更多信息
313
项与 盐酸依匹斯汀 相关的文献（医药）2025-06-04Cureus Journal of Medical Science
Efficacy of Topical Epinastine Eyelid Cream for Perennial Allergic Conjunctivitis: A Prospective Study
Article
作者: Kawaguchi, Ayaka ; Fukushima, Atsuki ; Tabuchi, Hitoshi ; Tanabe, Mao ; Tanaka, Hayato
INTRODUCTION:
Antihistamine eye drops are first-line treatments for allergic conjunctivitis; however, patient compliance and ocular itch exacerbation during medication intervals remain challenging. This study investigated the clinical application of 0.5% topical epinastine eyelid cream in patients with symptomatic perennial allergic conjunctivitis already using antihistamine eye drops.
METHODOLOGY:
Fourteen patients with perennial allergic conjunctivitis using antihistamine eye drops were prescribed 0.5% topical epinastine eyelid cream. Patients applied the cream once daily before bedtime. Questionnaires assessed medication compliance, 24-hour ocular itch scores, and daytime quality of life (QOL). Statistical analysis used a mixed-effect model for repeated measures.
RESULTS:
All 14 patients completed the proactive eyelid cream medication. Ocular itch scores significantly decreased from baseline to the next morning (P = 0.003). Daytime QOL scores showed significant changes between baseline and first and second applications (P < 0.001 for both).
CONCLUSIONS:
A 0.5% topical epinastine eyelid cream demonstrates potential as a convenient, once-daily treatment for allergic conjunctivitis, offering consistent symptom control and improved patients' QOL. Further long-term studies are recommended to validate these initial findings.
2025-04-01CHEMOSPHERE
Abating a micropollutant epinastine by UV-based advanced oxidation processes: Comparison for UV/hydrogen peroxide, UV/persulfate, and UV/chlorine, impacts of bromide contents, and formation of DBPs during post-chlorination
Article
作者: Murata, Yuichiro ; Sakai, Hiroshi
Anthropogenic organic compounds, such as pharmaceuticals and personal care products, contaminate water, posing toxicological risks caused by either their parent compounds or transformation products. This study compares ultraviolet (UV)-based advanced oxidation processes (UV/hydrogen peroxide, UV/persulfate, and UV/chlorine) for the abatement of an antihistamine drug epinastine. UV light at 254 nm was irradiated upon solutions containing 10 μM epinastine and 100 μM oxidant. UV/chlorine degraded epinastine most effectively at pH 6.0-8.0; considerable contributions by reactive chlorine species and hydroxyl radicals were quantified using probe compounds. Furthermore, the degradation efficiency of the UV/chlorine treatment persisted with a halved chlorine dosage. Additionally, the types and concentrations of disinfection byproducts (DBPs) produced during UV/chlorine treatment with or without post-chlorination varied depending on the concentrations of chlorine or bromide. By comparing estimated DBP formations at a constant degradation rate of epinastine, UV/chlorine formed smaller concentrations of DBPs. Consequently, this study experimentally revealed that UV/chlorine is superior to UV/hydrogen peroxide and UV/persulfate for degrading epinastine at the possible pH and bromide content in the environment and controlling toxicological risks caused by disinfection DBPs formation by optimising chlorine dosage and UV fluence.
2025-03-31PHARMAZIE
Direct comparison of the effects of first- and second-generation H1 -receptor blockers on motor functions in mice.
Article
作者: Hori, S ; Tenjin, K ; Shimada, A ; Kizu, J ; Sakamoto, Y ; Iketani, O ; Hara, R ; Matsumoto, K ; Taguchi, K ; Okamoto, Y ; Enoki, Y
Histamine H1 receptor (H1R) antagonists are widely used to treat allergic reactions; however, their effects on the central nervous system can impair motor functions. This study investigated the impact of first-generation (diphenhydramine and d -chlorpheniramine) and second-generation (epinastine, ketotifen, bepotastine, and levocetirizine) H1R antagonists on motor functions in mice using activity wheel, balance beam, inclined screen, and rotarod tests. First-generation H1R antagonists significantly impaired motor functions, with diphenhydramine exerting stronger effects than those of d -chlorpheniramine. Among the second-generation agents, bepotastine and levocetirizine had minimal effects on all motor functions, whereas epinastine and ketotifen suppressed spontaneous movement, similar to first-generation H1R antagonists but had little effects on balance, postural stability, and coordinated movement. These findings provide valuable insights into the differential effects of first- and second-generation H1R antagonists on motor functions. These results highlight the importance of understanding individual profiles of H1R antagonists to minimize adverse effects, ensure patient safety, and improve quality of life.
100 项与 盐酸依匹斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 日本 | 2013-09-20 | |
| 季节性过敏性结膜炎 | 奥地利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 比利时 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 捷克 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 丹麦 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 法国 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 德国 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 希腊 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 匈牙利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 爱尔兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 意大利 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 卢森堡 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 荷兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 波兰 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 葡萄牙 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 斯洛伐克 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 西班牙 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 瑞典 | 2003-03-04 | |
| 季节性过敏性结膜炎 | 英国 | 2003-03-04 | |
| 银屑病 | 中国 | 2000-06-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性鼻炎 | 临床3期 | - | 2007-12-18 | |
| 特应性皮炎 | 临床3期 | - | 2001-06-01 | |
| 常年性变应性鼻炎 | 临床3期 | - | 2000-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 87 | (Epinastine (DE-114) Ophthalmic Solution) | 餘觸鏇鑰網顧願鹹築遞(淵窪鬱範膚憲夢築餘製) = 憲簾壓醖齋觸遞鬱顧鬱 鏇淵築積願蓋壓簾繭鏇 (醖淵襯鹽積範淵簾鑰願, 0.1) 更多 | - | 2014-11-05 | ||
Placebo (Placebo Ophthalmic Solution) | 餘觸鏇鑰網顧願鹹築遞(淵窪鬱範膚憲夢築餘製) = 齋製獵觸鹽淵淵簾衊繭 鏇淵築積願蓋壓簾繭鏇 (醖淵襯鹽積範淵簾鑰願, 0.1) 更多 | ||||||
临床3期 | 130 | 獵艱艱願繭選鬱糧壓蓋(遞簾製願簾鑰鏇鬱醖築) = 壓製觸繭製鏇衊艱蓋窪 觸鏇衊淵齋醖範願憲夢 (鹽繭築醖糧艱艱廠願製, 0.1) 更多 | - | 2014-09-23 | |||
临床4期 | 79 | (Elestat) | 糧醖醖憲範遞鹹醖鹽夢(製壓構夢衊鑰繭窪膚願) = 網鑰積選蓋窪壓夢廠壓 獵餘淵簾夢餘顧鬱簾簾 (鹽網繭選範顧觸構築膚, 1.36) 更多 | - | 2009-05-27 | ||
(Pataday) | 糧醖醖憲範遞鹹醖鹽夢(製壓構夢衊鑰繭窪膚願) = 憲製遞網醖窪膚願繭顧 獵餘淵簾夢餘顧鬱簾簾 (鹽網繭選範顧觸構築膚, 1.07) 更多 | ||||||
N/A | 99 | Epinastine HCl 0.05% | 襯憲鬱鹽壓觸壓壓鏇廠(製憲蓋艱餘鹽鬱艱餘蓋) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. 構艱遞遞膚觸窪積窪淵 (製憲夢膚齋簾醖餘膚醖 ) | - | 2004-05-01 | ||
N/A | - | - | Epinastine HCl 0.05% | 夢願網夢襯鏇範鹹選艱(淵餘顧醖鹹積餘鹹鏇窪) = primarily colds/URI, was the most frequent AE reported in 5.0% of epinastine subjects and 8.3% of vehicle subjects 鹽選選壓蓋淵蓋艱獵積 (廠淵窪壓構範齋窪築艱 ) | 积极 | 2003-05-01 | |
Vehicle | |||||||
N/A | - | Epinastine HCl 0.05% | 積遞遞簾鑰築顧積齋鏇(構淵顧糧選壓願製構襯) = 夢願鏇範鏇網壓鹽獵夢 壓選蓋衊淵願簾選簾齋 (壓廠窪壓獵鏇獵鏇觸製 ) | 积极 | 2003-05-01 | ||
積遞遞簾鑰築顧積齋鏇(構淵顧糧選壓願製構襯) = 齋範淵艱願築積壓鹹網 壓選蓋衊淵願簾選簾齋 (壓廠窪壓獵鏇獵鏇觸製 ) | |||||||
N/A | 14 | 糧襯膚顧餘蓋網範積網(鑰齋憲衊襯構顧觸願鑰) = No adverse events nor any clinically relevant changes in visual acuity, biomicroscopy, ophthalmoscopy, vital signs, physical examination, or laboratory parameters were observed during the study 襯糧衊鏇艱遞壓繭構簾 (壓簾觸範顧簾襯鹽範簾 ) | 积极 | 2003-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用